Bicara Therapeutics
We are a clinical-stage biopharmaceutical company targeting head and neck squamous cell cancer with our leading drug candidate, ficerafusp alfa, a bifunctional antibody to target solid tumors. (Incorporated in Delaware) We are evaluating ficerafusp alfa in an ongoing Phase 1/1b clinical trial in the U.S. to treat patients with head and neck squamous cell cancer. […]
August 22, 2024 Read More